Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Pharma Equity Group
0,158
DKK
+0,32 %
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
13 seuraajaa
+0,32%
−25%
−36,75%
−32,11%
−63,37%
−67,46%
−50%
−84,48%
−99,39%
pharmaequitygroup.com/investors
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Liikevaihto
-
EBIT %
-
P/E -luku
-
Osinkotuotto %
-
Tavoitehinta
-
Suositus
-
Päivitetty
-
NASDAQ Copenhagen
PEG
Päivän matalin / päivän korkein hinta
0,156 / 0,162
DKK
Markkina-arvo
193,34 milj. DKK
Vaihto
6,6 t. DKK
Vaihtomäärä, kappaletta
41 t.
Viimeisimmät analyysit
Analyytikko
Claus Thestrup
CEO, Sweden
NäytäKaikki sisältötyypit
Consolidated Interim report 1 January – 30 September 2024
Pharma Equity Group (One-pager): Capital position strenghtened
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
Major shareholder announcement - Pharma Equity Group A/S
Managers’ transactions
Pharma Equity Group announces successful completion of directed issue of new shares
Pharma Equity Group: Directed issue with premium to closing price.
Pharma Equity Group announces issuance of new shares in a direct issue
Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights
Consolidated Interim Report 1 January – 30 June 2024
The Board of Directors' decision to issue convertible loans
Major shareholder announcement - Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
HCA Capital: Wrap up from 2024 Life Science seminar
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S